Dulaglutide vs Sermorelin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideGrowth Hormone PeptidesAnti-Aging & Longevity
Sermorelin- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Sermorelin is a bioidentical synthetic peptide comprising the first 29 amino acids of naturally occurring GHRH. It is FDA-approved for diagnostic use and widely prescribed off-label for anti-aging, stimulating growth hormone production in a natural pulsatile pattern that mimics the body's own rhythm.
- Half-Life
- ~5 days
- 10–20 minutes
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 200–500 mcg
- Frequency
- Once weekly
- 5–7 days per week
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Increases energy and vitality
- Improves body composition (more muscle, less fat)
- Enhances skin thickness and elasticity
- Strengthens immune system
- Improves sleep quality and REM sleep
- Supports bone density
- Enhances mental clarity and focus
- Safer than exogenous HGH — respects natural feedback loops
- FDA-approved for GH diagnostic use
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Injection site irritation
- Flushing
- Headache
- Dizziness
- +2 more
- Stacks With
- —
- —